TIDMAGL
Angle PLC
29 April 2016
For immediate release 29 April 2016
ANGLE plc ("the Company")
NEW PUBLICATIONS UTILISING PARSORTIX
New data from key opinion leaders on research undertaken with
the Parsortix system released at AACR and ISMRC conferences
ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company,
is pleased to announce that, following highly successful meetings
at AACR 2016 (the American Association for Cancer Research Annual
Meeting 2016 in New Orleans) and ISMRC (the 10th ISMRC
International Symposium on Minimal Residual Cancer: Liquid Biopsy
in Cancer Diagnostics and Treatment in Hamburg), several scientific
poster presentations published by key opinion leaders have now been
released to ANGLE's website.
The published poster presentations can be found at
http://www.angleplc.com/the-parsortix-system/download-files/ and
are as follows:
1) Cancer Research UK Manchester Institute: Detection and
molecular characterization of EpCAM positive and EpCAM negative
circulating tumour cells isolated from SCLC (small cell lung
cancer) patients using an epitope independent platform
2) Cancer Research UK Manchester Institute: Integration of RNA
and DNA blood borne cancer biomarkers
3) Cancer Research UK Manchester Institute: Combined circulating
tumour cell (CTC) and circulating tumor DNA (ctDNA) analysis of
blood from patients with pancreatic cancer
4) Heinrich-Heine University, Düsseldorf, Germany: The
combination of Parsortix(TM) system and CellCelector(TM)
micromanipulator enables the characterization of EpCAM negative
circulating tumor cells in breast cancer
The published poster presentations add to the growing published
evidence in support of the use of ANGLE's Parsortix system to
easily and effectively harvest cancer cells from the blood of
patients for analysis.
Key points in the published posters includes:
-- Development of a robust protocol for the isolation and
storage of CTCs. This is of great value for the incorporation of
the system in clinical trials;
-- Demonstration of the ability to store CTCs once harvested
from Parsortix for long periods, facilitating the use of the system
for banking samples;
-- Demonstration of single cell whole genome amplification (WGA)
of cells harvested by Parsortix. This allows sequencing of cell DNA
providing a mine of data on the cell and potentially how to treat
the patient;
-- Demonstration that combined CTC enrichment and cfDNA
isolation is readily achievable using a single blood collection
tube;
-- Illustration of how Parsortix works well with the single cell
CellCelector system enabling individual CTCs to be analysed. This
will enable research into cancer heterogeneity - an area of growing
interest;
-- Work flow demonstrates the ability to harvest EpCAM negative
cells (which cannot be harvested with antibody-based systems) using
Parsortix.
So far in 2016, ANGLE has participated in 5 cancer related
conferences:
-- Molecular Med TRI-CON 2016: March, San Francisco
-- World CDx: March, London
-- 10th ISMRC International Symposium on Minimal Residual
Cancer: Liquid Biopsy in Cancer Diagnostics and Treatment: March,
Hamburg
-- Molecular Diagnostics Europe: April, Lisbon
-- AACR 2016 (the American Association for Cancer Research
Annual Meeting 2016): April, New Orleans
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"There is now awareness of ANGLE's Parsortix system amongst key
researchers in the liquid biopsy field and we are making good
progress towards our aim of becoming the system of choice for
harvesting CTCs for analysis. It is also encouraging that
Heinrich-Heine University, Düsseldorf, is the first of our research
use customers to have published data using the system - we expect
to see many more in the future."
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Dr Christopher
Golden (Nominated adviser)
Russell Kerr, Olly Baxendale
(Sales) 020 7397 8900
FTI Consulting
Simon Conway, Mo Noonan,
Stephanie Cuthbert 020 3727 1000
Kimberley Ha (US) 001 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, China and
Australia and three extensive families of patents are being
progressed worldwide. The system is based on a microfluidic device
that captures live cells based on a combination of their size and
compressibility. Parsortix has a CE Mark for Europe and FDA
authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The Parsortix
system is designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALVLLLQZFXBBB
(END) Dow Jones Newswires
April 29, 2016 02:01 ET (06:01 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024